Rastilav Bahleda

Rastilav Bahleda

UNVERIFIED PROFILE

Are you Rastilav Bahleda?   Register this Author

Register author
Rastilav Bahleda

Rastilav Bahleda

Publications by authors named "Rastilav Bahleda"

Are you Rastilav Bahleda?   Register this Author

17Publications

594Reads

14Profile Views

Are phase I trials safe for older patients?

J Geriatr Oncol 2018 03 8;9(2):87-92. Epub 2017 Sep 8.

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif Cedex F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.08.012DOI Listing
March 2018

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Cancer Chemother Pharmacol 2017 Jun 19;79(6):1257-1265. Epub 2017 Apr 19.

Drug Development Department (DITEP), Gustave Roussy Cancer Centre, Université Paris-Saclay, 114 Rue Eduard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3303-zDOI Listing
June 2017

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Anticancer Drugs 2017 03;28(3):341-349

aGustave Roussy Cancer Centre, Paris-Saclay University, Drug Development Department (DITEP), Villejuif bHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite Cedex cHematology and Cellular Therapy Department, CIC INSERM 1415, University Hospital Centre, Tours, France dCancer Institute of New Jersey, New Brunswick, New Jersey, USA ePharmaMar, S.A., Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000457DOI Listing
March 2017

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Anticancer Drugs 2016 Apr;27(4):342-8

aMedical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium bInstitut de Cancerologie de l'Ouest, Boulevard Jacques Monod, Nantes St-Herblain Cedex cDrug Development Department, Gustave Roussy Cancer Campus, Villejuif, Cedex dUniversity Paris Sud, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000336DOI Listing
April 2016

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Medicine (Baltimore) 2014 Nov;93(24):333-9

From the Department of Nephrology (HI, VG, AB) and Pathology (PR), Pitié Salpêtrière Hospital, Paris; Department of Medical Oncology (BE, LD) and Gynecology (CL, PP), and Drug Development Department (DITEP) (RB, AH, JCS), Gustave Roussy Institute, VilleJuif; and Department of Nephrology (DS), UMRS 955 (DS), Henri Mondor Hospital, Creteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000000207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602430PMC
November 2014

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2192-204. Epub 2014 Feb 21.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Centre Francois Baclesse, CHU Côte de Nacre, Caen; Centre Léon Bérard Lyon, Lyon, France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; 12 de Octubre University Hospital, Madrid, Spain; Fox Chase Cancer Center, Philadelphia; Janssen Research & Development, Spring House, Pennsylvania; formerly University of Texas, MD Anderson Cancer Center, Houston, Texas; currently UC San Diego Moores Cancer Center, San Diego, California; Erasme University Hospital; Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; AZ Sint-Augustinus, Antwerp; Janssen Research & Development, Beerse, Belgium; Southampton University Hospitals NHS Trust, Southampton; Western General Hospital, Edinburgh; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; and Janssen Research & Development, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2200DOI Listing
April 2014

Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.

Kidney Int 2014 Feb 25;85(2):457-70. Epub 2013 Sep 25.

1] INSERM U 955, Equipe 21, Créteil, France [2] Université Paris-Est Creteil, Créteil, France [3] Service de Néphrologie, AP-HP, Groupe Hospitalier Henri Mondor-Albert Chenevier, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ki.2013.344DOI Listing
February 2014

Electrolyte disorders related to EGFR-targeting drugs.

Crit Rev Oncol Hematol 2010 Mar 28;73(3):213-9. Epub 2009 Apr 28.

Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2009.03.012DOI Listing
March 2010